Commercialization of plant-based vaccines from research and development to manufacturing.
The benefits of using plant-based oral vaccines are discussed. Transgenic maize expressing an antigen of transmissible gastroenteritis virus (TGEV) is reported as a model to demonstrate efficacy. Young pigs that were fed the TGEV corn orally were protected against challenge with virulent TGEV. Additional parameters important in providing a reliable and consistent supply of plant-based vaccines are discussed. Finally, vaccines developed in maize are evaluated for their potential to contaminate either the food supply or the environment.